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Gastric adenocarcinoma after gastric bypass for morbid obesity is rare but has been described. The diet restriction, weight loss,
and difficult assessment of the bypassed stomach, after this procedure, hinder and delay its diagnosis. We present a 52-year-
old man who underwent Roux-en-Y gastric bypass 2 years ago and whose previous upper digestive endoscopy was considered
normal. He presented with weight loss, attributed to the procedure, and progressive dysphagia. Upper digestive endoscopy revealed
stenosing tumor in gastric pouch whose biopsy showed diffuse-type gastric adenocarcinoma. He underwent total gastrectomy, left
lobectomy, distal pancreatectomy and splenectomy, segmental colectomy, and bowel resection with esophagojejunal anastomosis.
The histopathological analysis confirmed the presence of gastric cancer. The pathogenesis of gastric pouch adenocarcinoma is
discussed with a literature review.
1. Introduction
Obesity is a global problem, causing significant morbidity
and mortality [1]. Surgery is the only treatment in morbidly
obese patients causing effective weight loss and beneficial
long-term results. Postoperative outcome assessments have
clearly demonstrated the positive effect of bariatric surgery
on weight loss and subsequent improvement or resolution of
type 2 diabetes, obstructive sleep apnea, hypertension, and
dyslipidemias [1–3]. The original gastric bypass procedure
was performed in 1966 by Mason and Ito [4]. The Roux-en-
Y gastric bypass (RYGBP) is the most common procedure
currently performed for surgical treatment ofmorbid obesity.
Long-term complications may occur after bariatric surgery
but cancer is rare [5]. We report a case of gastric adenocarci-
noma after RYGBP and a review of the literature.
2. Case Report
A 52-year-old man presented with severe dysphagia 1 month
ago. On the examination, only pallor was noted. The labo-
ratory findings were normal, except for a microcytic anemia
with hemoglobin 8.9 g/dL. He had undergone RYGBP for the
treatment of morbid obesity 2 years ago, with Body Mass
Index (BMI) of 42 and type 2 diabetes. An upper digestive
endoscopy performed before surgery was considered normal
and revealedHelicobacter pylori (Hp) positive. He treated the
Hp using amoxicillin and clarithromycin and the endoscopy
was repeated showing Hp negative. After surgery he had
dietary restriction and lost 40 kg. Upper digestive endoscopy
revealed a stricture lesion in the gastric pouch and the
biopsies confirmed a signet-cell undifferentiated adenocarci-
noma.The computed tomography (CT scan) revealed a large
abdominal tumor affecting the excluded stomach and with
signs of invasion of the left hepatic lobe and the pancreas
(Figure 1).
The patient underwent total gastrectomy, including the
excluded stomach, distal pancreatectomy and splenectomy,
left hepatectomy and segmental colectomy with Roux-en-Y
esophagojejunal anastomosis, and primary colocolic anasto-
mosis because therewas true carcinomatosis invasion of adja-
cent organs (Figures 2 and 3). Twenty-five lymph-nodes were
resected and fourteen had metastasis. He had an uneventful
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Figure 1: CT scan showing the lesion affecting stomach and with
invasion of the left hepatic lobe and the pancreas.
Figure 2: Surgical specimen.
postoperative period. Chemotherapy was performed during
six months with good tolerance.
After 16 months, the patient was admitted to the emer-
gency with intestinal obstruction. Exploratory laparotomy
revealed numerous intestinal adhesions and bowel obstruc-
tion at multiple points. He underwent an ileocolic anastomo-
sis. Biopsies of the adhesionswere inconclusive. Nevertheless,
a PET-CT showed peritoneal carcinomatosis (Figures 4 and
5). Palliative chemotherapy was again introduced. His condi-
tion deteriorated, and he died after five months.
3. Discussion
The incidence of esophagogastric cancer after bariatric
surgery is rare; however, about 30 cases of adenocarcinoma
have been described in the last years [2, 5]. The etiology has
not been clearly elucidated, and possible factors could be
chronic reflux, stasis of food and acid in the pouch and lower
esophagus causing chronic mucosal irritation, and ischemic
damage due to the band when it is present [5, 6]. Retrograde
gastroscopies of the bypassed stomach after RYGBP (using
a pediatric colonoscope) found an 87% incidence of macro-
scopic gastritis, with microscopic confirmation in 45% of the
Figure 3: Detail of the tumor: gastric pouch and bypassed stomach
sectioned.
Figure 4: PET-CT showed peritoneal carcinomatosis in coronal
reconstruction.
cases and with progression to intestinal metaplasia in 10% [7–
9].
Endoscopy is considered the most sensitive diagnostic
modality to aid in the detection of premalignant dysplasia
or malignant gastric lesions [10]. Endoscopic access to the
excluded stomach might be possible through the afferent
limb of the previously loop gastrojejunostomy or through
the Roux limb, although this is technically challenging and
can be unreliable [11]. With a routine upper gastrointestinal
study, oral contrast is unlikely to reflux up the biliary limb
to reach the gastric remnant [7, 9, 12]. CT scanning is and
should remain the primary screening modality, where small
or early lesions might not be detected [11]. Percutaneous
puncture under ultrasound control is possible [13]. Finally,
if an endoscopic or radiologic diagnosis cannot be made,
access to the excluded stomach should be the next step in the
evaluation [14].
There are conditions that have been associated to greater
risk of gastric adenocarcinoma, such as family history, blood
type-A, hereditary nonpolyposis colon cancer, and the Li-
Fraumeni syndrome. There also exist precancerous lesions
such as adenomatous polyps, dysplasia, intestinal metaplasia,
and Menetrier’s disease. In patients with these conditions
with higher risk of developing gastric cancer, a resection of
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Figure 5: Peritoneal lesions with high SUV on PET-CT.
the bypassed stomach can be considered at the time ofRYGBP
[15].
The diagnosis of esophagogastric malignancies after
bariatric procedures can be difficult because weight loss,
vomiting, and inability to eat normal quantities of food can
be attributed to the expected results of surgery [2, 5].
The cases of gastric carcinomas after bariatric surgeries
previously reported by Raijman et al. [13], Lord et al. [16],
Khitin et al. [17], Corsini et al. [18], Escalona et al. [15],
Watkins et al. [11], and Harper et al. [19] presented a variety
of symptoms, but abdominal pain was more frequent, and
the usual evaluation methods were unsuccessful in provid-
ing a diagnosis. All patients reported were diagnosed with
adenocarcinoma in the excluded stomach after laparotomy;
therefore, this a difficult diagnosis. In our case, preoperative
upper digestive endoscopy was considered normal for 2
years, and after the surgery endoscopy diagnosed the disease,
because the tumor invaded the gastric pouch. The same
situation was described by Trincado et al. 5 years after gastric
bypass [20].
On the other hand, gastric adenocarcinomas have been
described after vertical banded gastroplasty (VBG). Ziraik et
al. [21], Papakonstantinou et al. [22], Belhaj et al. [23], Jain et
al. [6], and Chebib et al. [24], respectively, described gastric
adenocarcinomas in patients 2 years, 6 years, 10 years, 15
years, and 18 years afterVBG.These authors suggest that these
patients should bemonitored periodically by endoscopy after
operation.
TheHelicobacter pylori (Hp) is one of the etiologic factors
associated to gastric cancer [25, 26].Thus, due to the presence
of this bacteria in obese population undergoing Roux-en-Y
bypass gastric surgery and the concern that it may exacerbate
postoperative foregut symptoms and increase gastric cancer
risk, this led the surgeons to adopt a policy of Hp systematic
eradication preoperatively. Cerqueira et al. suggested that the
14-day triple therapy (proton pump inhibitor, clarithromycin,
and amoxicillin) is more effective than 7 days [27].
The authors, in recent publications, advise that an ade-
quate preoperative gastric evaluation by upper digestive
endoscopy should be performed on all candidates before
surgical treatment for obesity [28].
Finally, theremust be a high index of suspicion, if any sign
of malignancy was found during an endoscopy, for earlier
detection and treatment of gastric carcinoma, improving
patient outcomes.
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